Clinical Pharmacokinetics

, Volume 43, Issue 14, pp 1059–1068 | Cite as

Effect of Antacid on the Pharmacokinetics of Extended-Release Formulations of Tolterodine and Oxybutynin

  • Gayatri Sathyan
  • Roger R. Dmochowski
  • Rodney A. Appell
  • Cindy Guo
  • Suneel K. Gupta
Original Research Article

Abstract

Background

In general, extended-release (ER) formulations are designed to prolong the duration of efficacy and reduce the adverse effects of a drug. These formulations often contain the entire daily dose in a single tablet. Therefore, failure of the ER mechanism not only diminishes the desired benefits, but may temporarily expose the patient to drug concentrations higher than those released from a conventional tablet. In this study we determined whether pH has an effect on drug release from the ER formulations of oxybutynin (OROS® technology) and tolterodine (membrane coated beads) in vitro and in vivo.

Study design

In vitro studies were based on standardised dissolution experiments for each drug in media of different pH (artificial gastric fluid at pH 1.2, artificial intestinal fluid at pH 7.5, and water). In the two separate, identically designed in vivo studies, single doses of each drug were administered alone and with an antacid to male and female healthy volunteers aged 18–45 years. The randomised, crossover, open-label in vivo studies employed a validated assay to determine plasma concentrations of tolterodine and its metabolite 5-hydrox-ymethyl tolterodine (5-HM), or oxybutynin and its metabolite N-desethyloxybutynin.

Results

The in vitro study showed similar slow and steady drug release from ER-oxybutynin in each pH medium, with 64–71% released after 12 hours. Drug release from ER-tolterodine was steady and slow in artificial gastric fluid, with 72.5% of drug released after 12 hours. However, drug release was much faster in artificial intestinal fluid and water, where 69.8% and 69.1%, respectively, of the drug was released within 4 hours. These in vitro results were consistent with the findings of the in vivo studies. In vivo, the pharmacokinetic profile (peak plasma concentration [Cmax] and area under the concentration-time curve) of ER-oxybutynin was similar after administration with or without antacid, whereas Cmax values of both tolterodine and 5-HM increased significantly when ER-tolterodine was administered with antacid (p ≤ 0.017 vs ER-tolterodine alone).

Conclusions

Changes in pH affected the release of tolterodine from ER-tolterodine, while they had no effect on the release of oxybutynin from the proprietary ER technology used in ER-oxybutynin. The technology employed in ER formulations thus determines sensitivity of drug release to external factors.

Keywords

Drug Release Oxybutynin Tolterodine Poor Metaboliser Active Moiety 

Notes

Acknowledgments

These studies were funded by Ortho-McNeil/ALZA. Dr Sathyan, Ms Guo and Dr Gupta are employees of ALZA Corporation. Dr Dmochowski and Dr Appell are consultants to Ortho-McNeil and study investigators in clinical trials sponsored by Ortho-McNeil/ALZA and Pharmacia-Upjohn.

References

  1. 1.
    Public Health Service Agency for Health Care Policy and Research (PHSAHCPR). Clinical practice guidelines: urinary incontinence in adults. Washington, DC: US Department of Health and Human Services, 1996Google Scholar
  2. 2.
    Anderson R, Mobley D, Blank B, et al. Once-a-day controlled release versus immediate release oxybutynin chloride in the treatment of urinary urge incontinence. J Urol 1999; 161: 1809–12CrossRefPubMedGoogle Scholar
  3. 3.
    Nilvebrant L, Andersson KE, Gillberg P, et al. Tolterodine: a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195–207CrossRefPubMedGoogle Scholar
  4. 4.
    Pahlman I, Gozzi P. Serum protein binding of tolterodine and its major metabolites in humans and several animal species. Biopharm Drug Dispos 1999; 20: 91–9CrossRefPubMedGoogle Scholar
  5. 5.
    Detrol LA package insert. Kalamazoo (MI): Pharmacia & Upjohn, Dec 2000Google Scholar
  6. 6.
    Eckenhoff B, Theeuwes F, Urquhart J. Osmotically activated dosage forms for rate-controlled drug delivery. Pharm Technol 1981; 5: 35–44Google Scholar
  7. 7.
    Waldman SA, Morganroth J. Effects of food on the bioequivalence of different Verapamil sustained-release formulations. J Clin Pharmacol 1995; 35: 163–9CrossRefPubMedGoogle Scholar
  8. 8.
    Lukkari E, Castern-Kortekangas P, Juhakoski A, et al. Effect of food on the bioavailability of oxybutynin from a controlled release tablet. Eur J Clin Pharmacol 1996; 50: 221–3CrossRefPubMedGoogle Scholar
  9. 9.
    Ueno K, Kawashima S, Uemoto K, et al. Effect of food on nifedipine sustained-release preparation. DICP 1989; 23: 662–5CrossRefPubMedGoogle Scholar
  10. 10.
    Sathyan G, Hu W, Gupta SK. Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation. J Clin Pharmacol 2001; 41: 187–92CrossRefPubMedGoogle Scholar
  11. 11.
    Olsson B, Szamosi J. Food does not influence the pharmacokinetics of a new extended-release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin Pharmacokinet 2001; 40: 135–43CrossRefPubMedGoogle Scholar
  12. 12.
    US Pharmacopeia. The official compendia of standards: USP 25-NF 20. 1st ed. Rockville (MD); US Pharmacopeia, 2002Google Scholar
  13. 13.
    Tortara GJ, Anagnostakos NP. The chemical level of organization. In: Tortora GJ, Anagnostakos NP, editors. Principles of anatomy and physiology. 4th ed. San Francisco (CA): Harper & Row, 1984: 41Google Scholar
  14. 14.
    Gupta SK, Yih BM, Atkinson L, et al. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of Verapamil and norverapamil. J Clin Pharmacol 1995; 35: 1083–93CrossRefPubMedGoogle Scholar
  15. 15.
    Modi N, Wang B, Hu W, et al. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm Drug Dispos 2000; 21: 23–31CrossRefPubMedGoogle Scholar
  16. 16.
    Lecaillon JB, Massias P, Schoeller JP, et al. Influence of food on the absorption of metoprolol administered as an OROS delivery system in man. Br J Clin Pharmacol 1985; 19: 245–9SCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Gayatri Sathyan
    • 1
  • Roger R. Dmochowski
    • 2
  • Rodney A. Appell
    • 3
  • Cindy Guo
    • 1
  • Suneel K. Gupta
    • 1
  1. 1.Department of Clinical PharmacologyALZA CorporationMountain ViewUSA
  2. 2.Department of Urologic SurgeryVanderbilt University Medical CenterNashvilleUSA
  3. 3.Scott Department of UrologyBaylor College of MedicineHoustonUSA

Personalised recommendations